Clinical Trial Update: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness [Phase 2]

View source ↗

Summary

Phase 2 study evaluating atezolizumab added to the FLOT chemotherapy regimen versus FLOT alone in patients with gastric cancer or gastroesophageal junction aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Atezolizumab (atezolizumab)
• DOCETAXEL (DOCETAXEL)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING